Previous investigation proved that protein-based signature could predict tamoxifen treatment outcome in recurrent breast cancer and Long Noncoding RNA based signature could predict recurrence among ER+ breast cancer patients treated with tamoxifen (De Marchi et al., 2016; Wang et al., 2018). The gene discussed is ESR1; the disease is breast cancer.